Literature DB >> 2389682

The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A.

M P Pender1, G P Stanley, G Yoong, K B Nguyen.   

Abstract

Chronic relapsing experimental allergic encephalomyelitis was induced in Lewis rats by inoculation with guinea-pig spinal cord and complete Freund's adjuvant followed by treatment with low-dose cyclosporin A. In most animals, tail and limb weakness developed in a relapsing remitting pattern but in some these signs were persistent or progressive from onset. Histological studies during the early stages of clinically active disease (less than 25 days after inoculation) revealed inflammation and primary demyelination in the central nervous system (CNS), particularly the spinal cord, and in the peripheral nervous system (PNS), specifically the ventral and dorsal roots and dorsal root ganglia. Animals studied in the later stages of clinically active disease (greater than 28 days after inoculation) had extensive spinal cord demyelination but minimal PNS demyelination. In these animals, large plaques of demyelination with gliosis and prominent plasma cells occurred particularly in the thoracic spinal cord, and lesions of different ages were present within the spinal cord, CNS and PNS remyelination by oligodendrocytes and Schwann cells, respectively, was present in all animals studied later than 18 days after inoculation (the time of the first remission, if it occurred). In both early and late clinically active disease electron microscopy revealed macrophages invading and destroying CNS myelin sheaths. Active demyelination was sometimes found in regions of CNS remyelination, suggesting that remyelinated fibres were being attached. Axonal degeneration occurred in the spinal cord. During clinical remission there was CNS and PNS remyelination and much less inflammation; however, active demyelination still occurred to a limited degree.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2389682     DOI: 10.1007/bf00308921

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  35 in total

1.  Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis.

Authors:  H M Wiśniewski; A B Keith
Journal:  Ann Neurol       Date:  1977-02       Impact factor: 10.422

2.  A suppressor T-lymphocyte cell line for autoimmune encephalomyelitis.

Authors:  K E Ellerman; J M Powers; S W Brostoff
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

3.  A simple method for high resolution light microscopy of nervous tissue.

Authors:  M P Pender
Journal:  J Neurosci Methods       Date:  1985 Nov-Dec       Impact factor: 2.390

4.  Chronic relapsing EAE. Time course of neurological symptoms and pathology.

Authors:  H Lassmann; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1978-08-07       Impact factor: 17.088

5.  Demyelination and early remyelination in experimental allergic encephalomyelitis passively transferred with myelin basic protein-sensitized lymphocytes in the Lewis rat.

Authors:  M P Pender; K B Nguyen; D O Willenborg
Journal:  J Neuroimmunol       Date:  1989-12       Impact factor: 3.478

6.  Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse.

Authors:  A Brown; D E McFarlin; C S Raine
Journal:  Lab Invest       Date:  1982-02       Impact factor: 5.662

7.  Induction of recurrent experimental allergic encephalomyelitis with myelin basic protein.

Authors:  H Panitch; C Ciccone
Journal:  Ann Neurol       Date:  1981-05       Impact factor: 10.422

8.  A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease.

Authors:  H J Schluesener; R A Sobel; C Linington; H L Weiner
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

9.  Demyelination and neurological signs in experimental allergic encephalomyelitis.

Authors:  M P Pender
Journal:  J Neuroimmunol       Date:  1987-05       Impact factor: 3.478

10.  Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat.

Authors:  C H Polman; I Matthaei; C J de Groot; J C Koetsier; T Sminia; C D Dijkstra
Journal:  J Neuroimmunol       Date:  1988-02       Impact factor: 3.478

View more
  7 in total

1.  Ganglioside spinal cord changes in chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rats.

Authors:  E Zaprianova; D Deleva; B Hauttecoeur; M Bakalska; A Filchev
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

2.  Mice lacking phosphatidylinositol transfer protein-alpha exhibit spinocerebellar degeneration, intestinal and hepatic steatosis, and hypoglycemia.

Authors:  James G Alb; Jorge D Cortese; Scott E Phillips; Roger L Albin; Tim R Nagy; Bruce A Hamilton; Vytas A Bankaitis
Journal:  J Biol Chem       Date:  2003-06-04       Impact factor: 5.157

Review 3.  Cytokines and myelination in the central nervous system.

Authors:  Thomas Schmitz; Li-Jin Chew
Journal:  ScientificWorldJournal       Date:  2008-11-02

4.  Ganglioside changes in brain in chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat.

Authors:  E Zaprianova; D Deleva; A Filchev
Journal:  Neurochem Res       Date:  1998-11       Impact factor: 3.996

5.  Axonal injury heralds virus-induced demyelination.

Authors:  Ikuo Tsunoda; Li-Qing Kuang; Jane E Libbey; Robert S Fujinami
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

6.  Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats.

Authors:  I Huitinga; S R Ruuls; S Jung; N Van Rooijen; H P Hartung; C D Dijkstra
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

Review 7.  Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities.

Authors:  Rhoanne C McPherson; Stephen M Anderton
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-09       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.